Benzinga | Sep 24, 2021 07:20AM EDT

Cantor Fitzgerald Initiates Coverage On Cyclerion Therapeutics with Overweight Rating, Announces Price Target of $7

Cantor Fitzgerald initiates coverage on Cyclerion Therapeutics (NASDAQ:CYCN) with a Overweight rating and announces Price Target of $7.